Smiths Group share price slips as tariff jitters hit Europe — what investors watch next
19 January 2026
1 min read

Smiths Group share price slips as tariff jitters hit Europe — what investors watch next

London, January 19, 2026, 09:31 GMT — Regular session

  • Smiths Group shares dropped roughly 1% in early London trading, slipping back after last week’s surge.
  • Over the past year, the stock has surged ahead of the broader market, driven by investor attention on the group’s break-up and cash returns.
  • Smiths’ FY2026 interim results, due March 20, are the next major catalyst.

Shares of Smiths Group Plc (SMIN.L) slipped 1.1% to 2,584 pence in early Monday trading, falling from Friday’s 2,612 pence close. Early turnover was light, with around 62,500 shares changing hands. 1

European shares slumped early in the week after U.S. President Donald Trump warned of new tariffs linked to a spat over Greenland, weighing heavily on risk appetite. ING economists noted, “The rationale for higher tariffs is now even more political and less economic than in the first half of 2025.” 2

Smiths is central to this tape because the stock’s been trading as a restructuring play, yet the next concrete update won’t come for weeks. As macro news shifts rapidly, investors are probing how much of the recent premium sticks without fresh company-specific data to drive the price.

Smiths has started breaking up its old conglomerate structure, kicking off with a deal to sell its Interconnect unit to Molex for 1.3 billion pounds. That transaction is slated to close in the second half of fiscal 2026. At the same time, the company is pursuing parallel sale and demerger options for its Detection business. 3

In December, Smiths struck a deal to offload Smiths Detection to private equity firm CVC for £2 billion including debt. The company anticipated net cash proceeds around £1.85 billion after adjustments. Panmure Liberum analyst Alexandro da Silva O’Hanlon noted the price was at the high end of market expectations. 4

The group has pushed aggressively on capital returns. In November, it kicked off a £1 billion share buyback program, reducing its share count following a 3.5% rise in first-quarter organic revenue. 5

But the clean-up won’t be smooth. When Smiths revealed the break-up plan last year, CEO Roland Carter flagged “issues of national security” tied to key products. Still, he described selling off the Detection division as “feasible.” 6

The company says the proposed Detection sale is slated for the second half of calendar 2026, pending consultation with a French works council and “customary regulatory approvals” — a schedule that could face delays and political hurdles. 7

Smiths will release its FY2026 interim results on March 20. Investors will focus on any updated guidance about the disposal schedule, the speed of the buyback, and how cash returns could change as the portfolio shrinks. 8

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Severn Trent share price rises as UK water outages drag regulators back into focus
Previous Story

Severn Trent share price rises as UK water outages drag regulators back into focus

Legal & General share price slips as tariff jitters rattle London trade — what to watch next for LGEN
Next Story

Legal & General share price slips as tariff jitters rattle London trade — what to watch next for LGEN

Go toTop